Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study
Yıl: 2021 Cilt: 41 Sayı: 4 Sayfa Aralığı: 438 - 444 Metin Dili: İngilizce DOI: 10.5336/medsci.2021-84596 İndeks Tarihi: 21-03-2022
Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study
Öz: ABS TRACT Objective: Restless legs syndrome (RLS) is a neurological sensorimotor disease. Behavioral changes are little-known concern during the treatment and follow-up of RLS. The aim of the study is to highlight the behavioral changes associated with dopamine agonist treatment in the follow-up of RLS, such as dopamine dysregulation syndrome (DDS) and impulse control disorder (ICD). Material and Methods: We analyzed clinical data from RLS patients' files from the previous 15 years retrospectively. The patients receiving dopaminergic monotherapy for RLS, who came to follow-up on a regular basis and whose last examination was within the last 6 months were chosen. The average age of patients without behavioral changes was 48.60±9.21 years. Results: Of the patients’ complaints, legs were affected in 90.90%, arms and legs together were affected in 9.09%. Dopamine agonist-related changes were observed in 6 female patients. Mean age of these patients was 40.16±9.23 years old. They showed behavioral abnormalities such as uncontrolled drug use, shopping curiosity, hypersexuality, smoking, and space decoration. One patient presented with manic episode together with DDS. The average age of RLS patients who experienced behavioral changes was younger. Average dose at which behavior changes were observed was unclear since 4 of 6 patients with behavioral changes developed DDS. Despite using a regular-low dose agonist, the other two female patients showed ICD without DDS. Conclusion: With dopaminergic treatment, behavioral changes that may cause problems in family and social life can develop. When prescribing dopaminergic medications, it is important to ask if the patient has any behavioral changes and pay close attention in a busy polyclinic.
Anahtar Kelime: Huzursuz Bacaklar Sendromunda Dopamin Agonisti Tedavisi ile İlişkili Davranış Değişiklikleri: Retrospektif Bir Çalışma
Öz: Amaç: Huzursuz bacaklar sendromu (HBS) nörolojik bir sensörimotor hastalıktır. HBS’nin tedavi ve takibi sırasında ortaya çıkabilen davranış değişiklikleri yaygın değildir. Çalışmamızın amacı, HBS’nin takibinde dopamin agonisti tedavisi ile ilişkili dopamin disregülasyonu sendromu (DDS) ve dürtü kontrol bozukluğu (DKB) gibi davranış değişikliklerine dikkat çekmektir. Gereç ve Yöntemler: HBS tanısı olan hastaların dosya kayıtları geriye dönük olarak 15 yılı içine alacak şekilde incelendi. HBS için tek tip dopaminerjik tedavi kullanan, düzenli olarak kontrole gelen ve son kontrol muayenesi 6 ay içinde yapılmış olan hastalar seçildi. Davranış değişikliği olmayan hastaların ortalama yaşı 48,60±9,21 yıldı. Bulgular: Hastaların şikâyetlerinin %90,90’ı bacaklar, %9,09’u da kol ve bacaklar birlikte etkilenmiş olarak kaydedilmişti. Altı kadın hastada dopamin agonistleri ile ilişkili davranış değişiklikleri vardı. Bu hastaların ortalama yaşı 40,16±9,23 idi. Bu hastalar kontrol edemedikleri bağımlılık şeklinde yüksek doz ilaç kullanımı, aşırı alışveriş, cinsel yaşamda artış, kontrol edemedikleri sigara kullanımı, amaçsız ortam dekorasyonları şeklinde davranış değişiklikleri göstermişti. Bir hasta DDS ile beraber manik atağı tanısı almıştı. Davranış değişiklikleri yaşayan HBS hastalarının ortalama yaşı daha gençti. Davranış değişikliklerinin gözlendiği ortalama ilaç dozu, davranış değişiklikleri olan 6 hastanın 4’ünde DDS geliştiği için belirsizdi. Diğer 2 hasta düzenli-düşük doz bir agonist kullanmasına rağmen DKB gösterdi. Sonuç: Dopaminerjik tedavi ile aile ve sosyal yaşamda sorunlara neden olabilecek davranış değişikliklikleri gelişebilir. Dopaminerjik ilaçlar reçete edilirken, yoğun poliklinik şartlarında dikkatli olunmalı ve hastanın herhangi bir davranış değişikliği olup olmadığı iyi sorgulanmalıdır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Klingelhoefer L, Bhattacharya K, Reichmann H. Restless legs syndrome. Clin Med (Lond). 2016;16(4):379-82. [Crossref] [PubMed] [PMC]
- 2. Irlssg [Internet]. Diagnostic criteria.[Accessed 14 April 2021] Available from: [Link]
- 3. Kwatra V, Khan MA, Quadri SA, Cook TS. Differential diagnosis and treatment of restless legs syndrome: a literature review. Cureus. 2018;10(9):e3297. [Crossref] [PubMed] [PMC]
- 4. Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Ray Chaudhuri K, Brown RG, et al. Management of impulse control disorders in Parkinson's disease: controversies and future approaches. Mov Disord. 2015;30(2): 150-9. [Crossref] [PubMed] [PMC]
- 5. Vargas AP, Cardoso FEC. Impulse control and related disorders in Parkinson's disease. Arq Neuropsiquiatr. 2018;76(6):399-410. [Crossref] [PubMed]
- 6. Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33(1):81-7. [PubMed] [PMC]
- 7. Bayard S, Langenier MC, Dauvilliers Y. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome. Sleep. 2013; 36(10): 1501-7. [Crossref] [PubMed] [PMC]
- 8. Voon V, Schoerling A, Wenzel S, Ekanayake V, Reiff J, Trenkwalder C, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:117. [Crossref] [PubMed] [PMC]
- 9. Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, et al. Dopamine agonists and impulse control disorders: a complex association. Drug Saf. 2018;41(1):19-75. [Crossref] [PubMed] [PMC]
- 10. Stark AJ, Smith CT, Lin YC, Petersen KJ, Trujillo P, van Wouwe NC, et al. Nigrostriatal and mesolimbic D2/3 receptor expression in Parkinson's disease patients with compulsive reward-driven behaviors. J Neurosci. 2018; 38(13):3230-9. [Crossref] [PubMed] [PMC]
- 11. Rang HP, Dale MM, Ritter J, Flower RJ, Henderson G. Rang and Dale's Pharmacology. 7th ed. Edinburgh: Elsevier Churchill Livingstone; 2012. [Link]
- 12. Berke JD. What does dopamine mean? Nat Neurosci. 2018;21(6):787-93. [Crossref] [PubMed] [PMC]
- 13. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997; 278(5335):52-8. [Crossref] [PubMed]
- 14. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423-8. [Crossref] [PubMed] [PMC]
- 15. Taylor J, Anderson WS, Brandt J, Mari Z, Pontone GM. Neuropsychiatric complications of Parkinson disease treatments: importance of multidisciplinary care. Am J Geriatr Psychiatry. 2016;24(12):1171-80. [Crossref] [PubMed] [PMC]
- 16. Kon T, Ueno T, Haga R, Tomiyama M. The factors associated with impulse control behaviors in Parkinson's disease: a 2-year longitudinal retrospective cohort study. Brain Behav. 2018;8(8):e01036. [Crossref] [PubMed] [PMC]
- 17. Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675-84. [Crossref] [PubMed]
| APA | Varlıbaş F, Yüksel G, AKHAN Ö, Bastug Gul Z, Ergin B (2021). Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. , 438 - 444. 10.5336/medsci.2021-84596 |
| Chicago | Varlıbaş Figen,Yüksel Gülbün Asuman,AKHAN ÖZKAN,Bastug Gul Zeynep,Ergin Burçak Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. (2021): 438 - 444. 10.5336/medsci.2021-84596 |
| MLA | Varlıbaş Figen,Yüksel Gülbün Asuman,AKHAN ÖZKAN,Bastug Gul Zeynep,Ergin Burçak Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. , 2021, ss.438 - 444. 10.5336/medsci.2021-84596 |
| AMA | Varlıbaş F,Yüksel G,AKHAN Ö,Bastug Gul Z,Ergin B Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. . 2021; 438 - 444. 10.5336/medsci.2021-84596 |
| Vancouver | Varlıbaş F,Yüksel G,AKHAN Ö,Bastug Gul Z,Ergin B Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. . 2021; 438 - 444. 10.5336/medsci.2021-84596 |
| IEEE | Varlıbaş F,Yüksel G,AKHAN Ö,Bastug Gul Z,Ergin B "Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study." , ss.438 - 444, 2021. 10.5336/medsci.2021-84596 |
| ISNAD | Varlıbaş, Figen vd. "Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study". (2021), 438-444. https://doi.org/10.5336/medsci.2021-84596 |
| APA | Varlıbaş F, Yüksel G, AKHAN Ö, Bastug Gul Z, Ergin B (2021). Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. Türkiye Klinikleri Tıp Bilimleri Dergisi, 41(4), 438 - 444. 10.5336/medsci.2021-84596 |
| Chicago | Varlıbaş Figen,Yüksel Gülbün Asuman,AKHAN ÖZKAN,Bastug Gul Zeynep,Ergin Burçak Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. Türkiye Klinikleri Tıp Bilimleri Dergisi 41, no.4 (2021): 438 - 444. 10.5336/medsci.2021-84596 |
| MLA | Varlıbaş Figen,Yüksel Gülbün Asuman,AKHAN ÖZKAN,Bastug Gul Zeynep,Ergin Burçak Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. Türkiye Klinikleri Tıp Bilimleri Dergisi, vol.41, no.4, 2021, ss.438 - 444. 10.5336/medsci.2021-84596 |
| AMA | Varlıbaş F,Yüksel G,AKHAN Ö,Bastug Gul Z,Ergin B Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2021; 41(4): 438 - 444. 10.5336/medsci.2021-84596 |
| Vancouver | Varlıbaş F,Yüksel G,AKHAN Ö,Bastug Gul Z,Ergin B Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2021; 41(4): 438 - 444. 10.5336/medsci.2021-84596 |
| IEEE | Varlıbaş F,Yüksel G,AKHAN Ö,Bastug Gul Z,Ergin B "Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study." Türkiye Klinikleri Tıp Bilimleri Dergisi, 41, ss.438 - 444, 2021. 10.5336/medsci.2021-84596 |
| ISNAD | Varlıbaş, Figen vd. "Behavioral Changes Associated with Dopamine Agonist Treatment in the Follow-up of Restless Legs Syndrome: A Retrospective Study". Türkiye Klinikleri Tıp Bilimleri Dergisi 41/4 (2021), 438-444. https://doi.org/10.5336/medsci.2021-84596 |
